Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 5 , Pages 333-342 , October 2006

SIRS and group-B streptococcal sepsis in newborns: Pathogenesis and perspectives in adjunctive therapy

References 

  1. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol. 2005;17:338–344
  2. Mancuso G, Midiri A, Beninati C, Biondo R, Galbo S, Akira P, et al. Dual role of TLR2 and myeloid differentiation factor 88 in a mouse model of invasive group B streptococcal disease. J Immunol. 2004;172:6324–6329
  3. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163:316–321
  4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–1655
  5. Hayden WR. Sepsis terminology in pediatrics. J Pediatr. 1994;124:657–658
  6. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2–8
  7. Luck S, Torny M, d'Agapeyeff K, Pitt A, Heath P, Breathnach A, et al. Estimated early-onset group B streptococcal neonatal disease. Lancet. 2003;361:1953–1954
  8. Stoll BJ, Gordon T, Korones SB, Shankaran S, Tyson JE, Bauer CR, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr. 1996;129:72–80
  9. Bauer K, Zemlin M, Hummel M, Pfeiffer S, Karstaedt J, Steinhauser G, et al. Diversification of Ig heavy chain genes in human preterm neonates prematurely exposed to environmental antigens. J Immunol. 2002;169:1349–1356
  10. Haque KN. Definitions of bloodstream infection in the newborn. Pediatr Crit Care Med. 2005;6:S45–S49
  11. Lyytikainen O, Nuorti JP, Halmesmaki E, Carlson P, Uotila J, Vuento R, et al. Invasive group B streptococcal infections in Finland: a population-based study. Emerg Infect Dis. 2003;9:469–473
  12. Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, Schuchat A. Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics. 2002;110:690–695
  13. Heath PT, Balfour G, Weisner AM, Efstratiou A, Lamagni TL, Tighe H, et al. Group B streptococcal disease in UK and Irish infants younger than 90days. Lancet. 2004;363:292–294
  14. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis. Lancet Infect Dis. 2003;3:201–213
  15. Fluegge K, Supper S, Siedler A, Berner R. Serotype distribution of invasive group B streptococcal isolates in infants: results from a nationwide active laboratory surveillance study over 2years in Germany. Clin Infect Dis. 2005;40:760–763
  16. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285–291
  17. Healy CM, Palazzi DL, Edwards MS, Campbell JR, Baker CJ. Features of invasive staphylococcal disease in neonates. Pediatrics. 2004;114:953–961
  18. Rubens CE, Raff HV, Jackson JC, Chi EY, Bielitzki JT, Hillier SL. Pathophysiology and histopathology of group B streptococcal sepsis in Macaca nemestrina primates induced after intraamniotic inoculation: evidence for bacterial cellular invasion. J Infect Dis. 1991;164:320–330
  19. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol. 2000;165:3934–3940
  20. Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ, et al. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med. 2001;163:389–397
  21. Tamura GS, Kuypers JM, Smith S, Raff H, Rubens CE, et al. Adherence of group B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. Infect Immun. 1994;62:2450–2458
  22. Berner R, Csorba J, Brandis M. Different cytokine expression in cord blood mononuclear cells after stimulation with neonatal sepsis or colonizing strains of Streptococcus agalactiae. Pediatr Res. 2001;49:691–697
  23. Anderson DC, Hughes BJ, Smith CW. Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine. J Clin Invest. 1981;68:863–874
  24. Carr R. Neutrophil production and function in newborn infants. Br J Haematol. 2000;110:18–28
  25. Anderson DC, Abbassi O, Kishimoto TK, Koenig JM, Mclntire LV, Smith CW, et al. Diminished lectin-, epidermal growth factor-, complement binding domain-cell adhesion molecule-1 on neonatal neutrophils underlies their impaired CD18-independent adhesion to endothelial cells in vitro. J Immunol. 1991;146:3372–3379
  26. Shigeoka AO, Gobel RJ, Janatova J, Hill HR, et al. Neutrophil mobilization induced by complement fragments during experimental group B streptococcal (GBS) infection. Am J Pathol. 1988;133:623–629
  27. Rowen JL, Smith CW, Edwards MS. Group B streptococci elicit leukotriene B4 and interleukin-8 from human monocytes: neonates exhibit a diminished response. J Infect Dis. 1995;172:420–426
  28. Zilow EP, Hauck W, Linderkamp O, Zilow G, et al. Alternative pathway activation of the complement system in preterm infants with early onset infection. Pediatr Res. 1997;41:334–339
  29. Bohnsack JF, Takahashi S, Hammitt L, Miller DV, Aly AA, Adderson EE, et al. Genetic polymorphisms of group B streptococcus scpB alter functional activity of a cell-associated peptidase that inactivates C5a. Infect Immun. 2000;68:5018–5025
  30. Areschoug T, Stalhammar-Carlemalm M, Karlsson I, Lindahl G, et al. Streptococcal beta protein has separate binding sites for human factor H and IgA-Fc. J Biol Chem. 2002;277:12642–12648
  31. Albanyan EA, Vallejo JG, Smith CW, Edwards MS, et al. Nonopsonic binding of type III Group B streptococci to human neutrophils induces interleukin-8 release mediated by the p38 mitogen-activated protein kinase pathway. Infect Immun. 2000;68:2053–2060
  32. Henneke P, Takeuchi O, Malley R, Lien E, Ingalls RR, Freeman MW, et al. Cellular activation, phagocytosis, and bactericidal activity against group B streptococcus involve parallel myeloid differentiation factor 88-dependent and independent signaling pathways. J Immunol. 2002;169:3970–3977
  33. Henneke P, Osmers I, Bauer K, Lamping N, Versmold HT, Schumann RR, et al. Impaired CD14-dependent and independent response of polymorphonuclear leukocytes in preterm infants. J Perinat Med. 2003;31:176–183
  34. Marodi L, Leijh PC, van Furth R. Characteristics and functional capacities of human cord blood granulocytes and monocytes. Pediatr Res. 1984;18:1127–1131
  35. Levy O. Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol. 2004;76:909–925
  36. Bowdy BD, Marple SL, Pauly TH, Coonrod JD, Gillespie MN, et al. Oxygen radical-dependent bacterial killing and pulmonary hypertension in piglets infected with group B streptococci. Am Rev Respir Dis. 1990;141:648–653
  37. Poyart C, Pellegrini E, Gaillot O, Boumaila C, Baptista M, Trieu-Cuot P, et al. Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect Immun. 2001;69:5098–5106
  38. Cheng Q, Carlson B, Pillai S, Eby R, Edwards L, Olmsted SB, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun. 2001;69:2302–2308
  39. Kallman J, Schollin J, Schalen C, Erlandsson A, Kishlstrom E, et al. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 1998;78:F46–F50
  40. Kenzel S, Mancuso G, Malley R, Teti G, Golenbock DT, Henneke P. C-Jun kinase is a critical signaling molecule in a neonatal model of group B streptococcal sepsis. J Immunol. 2006;176:3181–3188
  41. LeVine AM, Reed JA, Kurak KE, Cianciolo E, Whitsett JA, et al. GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest. 1999;103:563–569
  42. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med. 2002;30:S207–S213
  43. Forster-Waldl E, Sadeghi K, Tamandl D, Gerhold B, Hallwirth U, Rohrmeister K, et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res. 2005;58:121–124
  44. Yan SR, Qing G, Byers DM, Stadnyk AW, Al-Hertani W, Bortolussi R, et al. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Infect Immun. 2004;72:1223–1229
  45. Du X, Poltorak A, Silva M, Beutler B, et al. Analysis of Tlr4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol Dis. 1999;25:328–338
  46. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR, et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol. 2004;173:4627–4634
  47. Krueger M, Nauck MS, Sang S, Hentschel R, Wieland H, Berner R, et al. Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants. Biol Neonate. 2001;80:118–123
  48. Berner R, Welter P, Brandis M. Cytokine expression of cord and adult blood mononuclear cells in response to Streptococcus agalactiae. Pediatr Res. 2002;51:304–309
  49. Henneke P, Takeuchi O, van Strijp JA, Guttormsen HK, Smith JA, Schromm AB, et al. Novel engagement of CD14 and multiple toll-like receptors by group B streptococci. J Immunol. 2001;167:7069–7076
  50. Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, et al. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005;174:6449–6455
  51. Travassos LH, Girardin SE, Philpott DJ, Blanot D, Nahori MA, Werts C, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep. 2004;5:1000–1006
  52. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D, et al. Cutting edge: recognition of gram-positive bacterial cell wall components by the innate immune system occurs via toll-like receptor 2. J Immunol. 1999;163:1–5
  53. Baker CJ, Kasper DL, Davis CE. Immunochemical characterization of the “native” type III polysaccharide of group B Streptococcus. J Exp Med. 1976;143:258–270
  54. Martin TR, Ruzinski JT, Rubens CE, Chi EY, Wilson CB, et al. The effect of type-specific polysaccharide capsule on the clearance of group B streptococci from the lungs of infant and adult rats. J Infect Dis. 1992;165:306–314
  55. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, et al. Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol. 1998;160:4535–4542
  56. Henneke P, Golenbock DT. TIRAP: how Toll receptors fraternize. Nat Immunol. 2001;2:828–830
  57. Fluegge K, Schweier O, Schiltz E, Batsford S, Berner R, et al. Identification and immunoreactivity of proteins released from Streptococcus agalactiae. Eur J Clin Microbiol Infect Dis. 2004;23:818–824
  58. Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection: no longer in its infancy. Mol Microbiol. 2004;54:23–31
  59. Ahrens P, Kattner E, Kohler B, Hartel C, Seidenberg J, Segerer H, et al. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res. 2004;55:652–656
  60. Harding D, Dhamrait S, Millar A, Humphries S, Marlow N, Whitelaw A, et al. Is interleukin-6 -174 genotype associated with the development of septicemia in preterm infants?. Pediatrics. 2003;112:800–803
  61. Gopel W, Hartel C, Ahrens P, Konig I, Kattner E, Kuhls E, et al. Interleukin-6 -174-genotype, sepsis and cerebral injury in very low birth weight infants. Genes Immun. 2006;7:65–68
  62. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med. 1999;27:807–814
  63. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2001;[CD001239]
  64. Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropaenia. Cochrane Database Syst Rev. 2003;[CD003956]
  65. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377
  66. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S527–S533
  67. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–873
  68. Gordon A, Jeffery HE. Antibiotic regimens for suspected late onset sepsis in newborn infants. Cochrane Database Syst Rev. 2005;[CD004501]
  69. Woodgate P, Flenady V, Steer P. Intramuscular penicillin for the prevention of early onset group B streptococcal infection in newborn infants. Cochrane Database Syst Rev. 2004;[CD003667]
  70. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874
  71. Treszl A, Kocsis I, Szathmari M, Schuler A, Heninger E, Tulassay T, et al. Genetic variants of TNF-[FC12]a, IL-1beta, IL-4 receptor [FC12]a-chain, IL-6 and IL-10 genes are not risk factors for sepsis in low-birth-weight infants. Biol Neonate. 2003;83:241–245
  72. Bessler H, Osovsky M, Sirota L. Association between IL-1ra gene polymorphism and premature delivery. Biol Neonate. 2004;85:179–183

PII: S1744-165X(06)00032-1

doi: 10.1016/j.siny.2006.03.003

Seminars in Fetal & Neonatal Medicine
Volume 11, Issue 5 , Pages 333-342 , October 2006

Article Tools

* Image Usage & Resolution